РусскийEnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Chorna I.V., Vysotsky I.Yu.

    MOLECULAR MECHANISMS OF MULTIDRUG RESISTANCE OF CANCER CELLS TO ANTICANCER DRUGS


    About the author: Chorna I.V., Vysotsky I.Yu.
    Heading LITERATURE REVIEWS
    Type of article Обзорная статья
    Annotation The review of contemporary literature is given devoted to development of multidrug resistance (MDR) of cancer cells to cytotoxic drugs. Therefore nowadays a search of molecular markers of tumor cells sensitivity to anticancer therapy is carried out. It will allow to select the optimal treatment for individual patient according to a genetic characteristics of particular tumor.
    Tags multidrug resistance, cancer cells, chemotherapy, apoptosis
    Bibliography
    • Барышников А.Ю. Проблемы лекарственной резистентности / А.Ю. Барышников, Е.В. Степанова // Материалы третьей ежегодной Российской онкологической конференции, 29 ноября - 1 декабря 1999 г. – Санкт-Петербург, 1999. – C. 9-19.
    • Копнин Б.П. Неопластическая клетка: основные свойства и механизмы их возникновения / Б.П. Копнин // Практическая онкология. – 2002. – Т. 3, №4. – С. 229-235.
    • Копнин Б.П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза / Б.П. Копнин // Биохимия. – 2000. – Т.65, №1. – С. 5-33.
    • Корекція порушень метилування ДНК як можливий шлях модуляції лікарської резистентності злоякісних клітин / В.Ф. Чехун, Д.О. Микитенко, Н.Ю. Лук’янова, I.П. Погрібний // Укр. біохім. журн. – 2006. – Т. 78, №6. – С. 5-14.
    • Маркеры множественной лекарственной устойчивости при острых миелоидных лейкозах / О.Д. Захаров, Е.Ю. Рыбалкина, М.А. Волкова, А.А. Ставровская // Онкогематология. – 2006. – Т. 1, №1-2. – С. 9-15.
    • Множественная лекарственная устойчивость и возможные пути ее преодоления / В.Н. Кузнецов, Д.А. Касымов, С.Г. Титов, В.К. Яхьяев // Журнал теоретической и клинической медицины. – 2004. – Т.18, №4. – С. 83-87.
    • Полушкина И.Н. Молекулярно-биологические маркеры, характеризующие апоптоз, пролиферацию и ангиогенез при раке яичников / И.Н. Полушкина, Ж.Н. Дбар, Е.В. Степанова // Вестник РОНЦ им. Блохина РАМН. – 2002. – №4. – C.10-17.
    • Северин Е.С. Проблемы и перспективы современной противоопухолевой терапии / Е.С. Северин, А.В. Родина // Успехи биологической химии. – 2006. – Т. 46.– С.43-64.
    • Ставровская А.А. Клеточные механизмы множественной лекарственной устойчивости опухолевых клеток / А.А. Ставровская // Биохимия. – 2000. – Т. 65, №1. – С. 112-126.
    • Чумаков П.М. Белок р53 и его универсальные функции в многоклеточном организме / П.М. Чумаков // Успехи биологической химии. – 2007. – Т. 47, №1. – С. 3-52.
    • A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer / L. Gilbert, L.J. Elwood, M. Merino [et al.] // J. Clin. Oncol. – 1993. – Vol. 11, №1. – P. 49-58.
    • A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence / M. Sawicka, M. Kalinowska, J. Skierski, W. Lewandowski // J. Pharm. Pharmacol. – 2004. – Vol. 56, №9. – Р. 1067-1081.
    • Amaral J.D. The role of p53 in apoptosis / J.D. Amaral // Discovery Medicine. – 2010. – Vol. 9, №45. – P. 145-152.
    • Analysis of glutathione: implication in redox and detoxification / A. Pastore, G. Federici, E. Bertini, F. Piemonte // Clin. Chim. Acta. – 2003. – Vol. 333, №1. – P. 19-39.
    • Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer / S. Kang, W. Ju, J.W. Kim [et al.] // Exp. Mol. Med. – 2006. – Vol. 38, №3. – P. 320-324.
    • Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis / T. Mikami, N. Yanagisawa, H. Baba, M. Koike, I. Orayasu // Cancer. – 1999. – Vol. 85, №2. – P. 318-325.
    • Baguley B.C. Multidrug resistance in cancer / B.C. Baguley // Methods Mol. Biol. – 2010. – Vol. 596. – P. 1-14.
    • Burlacu A. Regulation of apoptosis by Bcl-2 family proteins / A. Burlacu // J. Cell Mol. Med. – 2003. – Vol. 7, №3. – Р. 249-257.
    • Conseil G. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters / G. Conseil, R.G. Deeley, S.P. Cole // Pharmacogenet. Genomics. – 2005. – Vol. 15, №8. – Р. 523-533.
    • DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy / K.A. Olaussen, A. Dunant, P. Fouret [et al.] // N. Engl. J. Med. – 2006. – Vol. 355, №10 – P. 983-991.
    • Doyle A.L. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) / A.L. Doyle, D.D. Ross // Oncogene. – 2003. – Vol. 22, №47. – Р.7340-7358.
    • Elmore S. Apoptosis: A Review of programmed cell death / S. Elmore // Toxicologic Pathology. – 2007. – Vol. 35, №4. – P. 495-516.
    • Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers / M.F. Fromm // Trends Pharmacol. Sci. – 2004. – Vol. 25, №8. – P. 423-429.
    • Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells / L. Lan, T. Hayashi, R.M. Rabeya [et al.] // DNA Repair. – 2004. – Vol. 3, №2. – P. 135-143.
    • Gatti L. Overview of Tumor Cell Chemoresistance Mechanisms / L. Gatti, F. Zunino // Methods Mol. Med. – 2010. – Vol. 111, №1. – P. 127-148.
    • Ghezzi P. Glutathionylation pathways in drug response / P. Ghezzi, P. Di Simplicio // Curr. Opin. Pharmacol . – 2007. – Vol. 7, №4. – P. 398-403.
    • Gillet J.P. Chemotherapy-induced resistance by ATP-binding cassette transporter genes / J.P. Gillet, T. Efferth, J. Remacle // Biochim. Biophys. Acta. – 2007. – Vol. 1775, №2. – P. 237-262.
    • Gillet J.P. Mechanisms of multidrug resistance in cancer / J.P. Gillet, M.M. Gottesman // Methods Mol. Biol. – 2010. – Vol. 596. – P. 47-76.
    • Gonzalez-Angulo A.M. Overview of resistance to systemic therapy in patients with breast cancer / A.M. Gonzalez-Angulo, F. Morales-Vasquez, G.N. Hortobagyi // Adv. Exp. Med. Biol. – 2007. – Vol. 608, №1. – P. 1-22.
    • Higgins C.F. Multiple molecular mechanisms for multidrug resistance transporters / C.F. Higgins // Nature. – 2007. – Vol. 446, № 7137. – P. 749-757.
    • Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine microalgal polysaccharide / K. Umemura, K. Yanase, M. Suzuki [et al.] // Biochem. Pharmacol. – 2003. – Vol. 66, №3. – P. 481-487.
    • Jones P.M. The ABC transporter structure and mechanism: perspectives on recent research / P.M. Jones, A.M. George // Cell Mol. Life Sci. – 2004. – Vol. 61, №6. – P.682-699.
    • Kim E. Wild-type p53 in cancer cells: when a guardian turns into a blackguard / E. Kim, A. Giese, W. Deppert // Biochem. Pharmacol. – 2009. – Vol. 77, №1. – P. 11-20.
    • Longley D.B. Molecular mechanisms of drug resistance / D.B. Longley, P.G. Johnston // J. Pathol. – 2005. – Vol. 205, №2. – P. 275-292.
    • Martin L.P. Platinum resistance: the role of DNA repair pathways / L.P. Martin, T.C. Hamilton, R.J. Schilder // Clin. Cancer Res. – 2008 – Vol. 14, №5. – P. 1291-1295.
    • Maximov G.K. The role of p53 tumor-suppressor protein in apoptosis and cancerogenesis / G.K. Maximov, K.G. Maximov // Biotechnol. & Biotechnol. EQ. – 2008. – Vol. 22, №2. – P. 664-668.
    • Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme / Y. Pommier, P. Pourquier, Y. Fan, D. Strumberg // Biochim. Biophys. Acta. – 1998. – Vol. 1400, №1-3. – P. 83-106.
    • O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy / B. Verbeek, T.D. Southgate, D.E. Gilham, G.P. Margison // Br. Med. Bull. – 2008. – Vol. 85, №1. – P. 17-33.
    • Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents / C.K. Youn, M.H. Kim, H.J. Cho [et al.] // Cancer Res. – 2004. – Vol. 64, №14. – P.4849-4857.
    • Rastogi R.P. Apoptosis: molecular mechanisms and pathogenicity / R.P. Rastogi, Richa, R.P. Sinha // EXCLI Journal. – 2009. – Vol. 8. – P. 155-181.
    • Rodriguez-Nieto S. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment / S. Rodriguez-Nieto, B. Zhivotovsky // Curr. Pharm.  Des. – 2006. – Vol. 12, №34. – P. 4411-4425.
    • Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells / S. Meschini, M. Marra, A. Calcabrini [et al.] // Toxicol. In Vitro. – 2002. – Vol. 16, №4. – P. 389-398.
    • Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance / Z.H. Siddik // Oncogene. – 2003. – Vol. 22, №47. – P. 7265-7279.
    • Thomas H. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting pglycoprotein / H. Thomas, H.M. Coley // Cancer Control. – 2003. – Vol. 10, №2. P. 159-165.
    • Thottassery J.V., Zambetti G.P., Arimori K., Schuetz E.G., Schuetz J.D. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents // Proc. Natl. Acad. Sci. USA. – 1997. – Vol. 94, №20. – P. 11037-11042.
    • Townsend D.M. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets / D.M. Townsend, V.L. Findlay, K.D. Tew // Methods Enzymol. – 2005. – Vol. 401. – P. 287-307.
    Publication of the article «World of Medicine and Biology» №2(29), 2011 year, 189-193 pages, index UDK 616-006:576